Calcipotriene 0.005% and betamethasone dipropionate 0.064% topical suspension, 60 g
Indications and Usage:
Taclonex Scalp (calcipotriene 0.005% and betamethasone dipropionate 0.064%) Topical Suspension is indicated for the topical treatment of moderate to severe psoriasis vulgaris of the scalp in adults 18 years of age and older. Taclonex Scalp should be applied to affected areas on the scalp once daily for 2 weeks or until cleared and may be continued for up to 8 weeks. The maximum weekly dose should not exceed 100 g. FOR TOPICAL USE ONLY. Taclonex Scalp should not be applied to the face, axillae, or groin. Taclonex Scalp is not for oral, ophthalmic, or intravaginal use. Taclonex Scalp should not be used in patients with hypersensitivity to any of its components or atrophy at the treatment site. The safety and efficacy of Taclonex Scalp have not been evaluated in patients with known or suspected disorders of calcium metabolism. Taclonex Scalp has not been evaluated in patients with erythrodermic, exfoliative, or pustular psoriasis or in patients with severe renal insufficiency or severe hepatic disorders.
Side Effects and Contraindications:
Hypercalcemia and hypercalciuria have been observed with Taclonex Scalp. Reversible hypothalamic-pituitary-adrenal (HPA)-axis suppression has also been observed with Taclonex Scalp in combination with Taclonex Ointment. The rate of adrenal suppression due to the combination of Taclonex Ointment and Taclonex Scalp increased with treatment duration. Systemic absorption may require evaluation for HPA-axis suppression. Potent corticosteroids, use on large areas, prolonged use, or occlusive use may increase systemic absorption. Cushingís syndrome, hyperglycemia, and unmasking of latent diabetes mellitus can also result from systemic absorption of topical corticosteroids. In clinical trials with Taclonex Scalp, the most frequent adverse reactions were folliculitis and burning sensation of skin. Local adverse reactions may include atrophy, striae, irritation, acneiform eruptions, hypopigmentation, and allergic contact dermatitis and may be more likely with occlusive use or more potent corticosteroids.